Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 63

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 63
---
 Actual         | ​ | ​ | ​ | Payout % |   |        |   | ​ | ​ |
| ​ | ​ | 1. CRL Revenue(1) | ​ | ​ | ​ | ​         | ​ | 50% | ​ | ​ | ​ | ​ | $4,307 million | ​ | ​ | ​ | $4,050 million | ​ | ​ | ​ | ​        | ​ | 40.45% | ​ | ​ | ​ |
| ​ | ​ | 2. CRL OI(2)      | ​ | ​ | ​ | ​         | ​ | 50% | ​ | ​ | ​ | ​ | $911.9 million | ​ | ​ | ​ | $805.9 million | ​ | ​ | ​ | ​        | ​ | 40.45% | ​ | ​ | ​ |

(1) For purposes of this 2024 EICP performance goal, revenue was based on the Company’s net revenue, which was adjusted to neutralize for the actual impacts of fluctuating foreign exchange rates. (2) For purposes of this 2024 EICP performance goal, consistent with the way the Company reports its non-GAAP financial results in its earnings releases, OI excluded the following items: the amortization of intangible assets and the purchase accounting step-up adjustment on inventory and certain long term biological assets, inclusive of the acceleration of amortization related to certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment; other charges and adjustments related to our acquisitions and divestitures; expenses associated with evaluating and integrating acquisitions and divestitures, including advisory fees and certain other transaction-related costs, as well as fair value adjustments associated with contingent consideration; charges, gains, and losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our restructuring initiatives; a goodwill impairment charge within the Biologics Solutions reporting unit recognized due to the loss of key customers; certain legal costs in our Safety Assessment business related to U.S. government investigations into the NHP supply chain; and an inventory charge incurred within Discovery Safety Assessment segment associated with the Cambodia-sourced non-human primates. The Committee determined that it was appropriate to exclude these items as they are outside our normal core operations.

51

For historical comparative purposes, the percentages of targeted vs. actual annual cash incentive awards for our current named executives for fiscal years 2017-2024 (